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perspective, more research is needed to identify the reasons for augmentation in chil-
dren and adolescents with ADHD (e.g., duration of effect, titration) and to examine 
patterns of medication taking throughout the day.
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OBJECTIVES: Poor continuity of care occurs when patients do not follow-up after 
being discharged from the hospital. In bipolar disorder problems with continuity of 
care and medication adherence may lead to expensive relapses. The objectives of this
research were threefold: 1) examine the frequency of poor continuity of care for indi-
viduals with bipolar disorder; 2) identify the predictors of poor continuity of care; 
and 3) evaluate the potential increased psychiatric hospitalization costs. METHODS:
Premier linked their PerspectiveTM Comparative Database (PCD), the largest, most
detailed, U.S. hospital database, with the administrative claims from a large managed 
care organization. We identiﬁ ed 319 individuals who had a primary discharge diag-
nosis of bipolar disorder in the PCD and who maintained continuous eligibility for
the 60 days prior and the 180 days following the hospitalization. Good continuity of 
care was operationally deﬁ ned as the presence of a psychiatric visit in the 60 days 
following discharge. Propensity scores were used to correct for background differences
between patients with good continuity of care and patients with poor continuity of 
care. RESULTS: A total of 34.5% of individuals had poor continuity of care. Prior to
discharge, individuals who would later have poor continuity of care could be identi-
ﬁ ed. Some variables that independently predicted later poor continuity of care included
no psychotherapy visits, no psychiatric visits, substance use diagnoses, and psychiatric
hospitalizations. After correcting for background differences, patients with poor con-
tinuity of care had reduced mood stabilizer use (94 vs. 116 days, p  0.008) and twice 
the psychiatric hospitalization charges ($10,027 vs. $4,892, p  0.03). CONCLU-
SIONS: One in three individuals with bipolar disorder did not have a psychiatric 
follow-up visit after discharge from the hospital. This poor continuity of care appears
to lead to decreased medication adherence and increased psychiatric hospitalizations.
An effective, targeted intervention could potentially prevent relapses and reduce health 
care costs.
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OBJECTIVES: This research examines the relationship of ethnicity and income with 
attention-deﬁ cit hyperactivity disorder (ADHD) treatment patterns among subjects on 
medications of different durations. METHODS: Claims of newly treated ADHD sub-
jects, aged q6 years, initially treated with stimulants, and continuously enrolled in a
US commercial health plan 6 months prior and 12 months after their ﬁ rst prescription 
(January 1, 2004 “C September 30, 2006) were studied. Subjects took short- (SAS)
intermediate- (IAS) or long-acting (LAS) stimulant medication for ADHD. Persistence 
was deﬁ ned as the number of days on initial therapy. Adherence was deﬁ ned as the 
number of days of initial therapy divided by persistent days. Differences in mean per-
sistence and adherence, dosing, switching and augmentation among ethnicities (non-
Hispanic Caucasians [NHC], Hispanics [H] and African Americans [AA]) and among 
income levels were assessed. RESULTS: Among children on LAS (n  12,796), NHC 
had the highest mean adherence (0.56) and the longest mean persistence (251 days) 
(p  0.0001 among groups), while AA had the shortest persistence (222 days) and the
lowest adherence (0.46) (p  0.0001 among groups). Similarly, among adults receiving 
LAS (n  8422), NHC had the highest adherence (0.58) and the longest persistence 
(225 days). Persistence was again shortest among AA (194 days; p  0.037 among 
groups), while adherence was equally low for AA and H (0.52; p  0.002 among 
groups). Within treatment groups of different durations, the propensity of subjects to 
change dose, switch or augment their medication varied according to ethnicity. While 
no signiﬁ cant relationship between race/ethnicity and either adherence or persistence 
was found among children or adults receiving SAS or IAS, the IAS and LAS groups 
showed greater persistence and adherence with increased income levels in some sub-
jects. CONCLUSIONS: Persistence and adherence to stimulant medications differed 
by race/ethnicity and income. This may have implications for the optimal management
of ADHD.
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BACKGROUND: Treatment-resistant depression (TRD) is severely disabling with no
treatments proven to provide sustainable beneﬁ t when multiple medications, psycho-
therapy, and electroconvulsive therapy fail. (Malone, 2008). OBJECTIVES: The 
perform a systematic review of published literature to evaluate recent health economics
and outcomes research related to TRD to inform future research initiatives. 
METHODS: English language citations in PubMed and Cochrane Library from 
January 1, 2000–October 1, 2008 were systematically reviewed. Standard search terms
deﬁ ned disease states (including TRD, severe depression (SD), chronic depression
(CD), major depressive disorders (MDD), and suicidality); interventions (deep brain
stimulation, electroconvulsive therapy, transcranial magnetic stimulation and vagus
nerve stimulation); and outcomes (treatment outcomes, presenteeism, symptom
burden, resource utilization, productivity, cost, economics, and quality of life(QOL)). 
RESULTS: Initial searches yielded 8811 citations, narrowed to 5626 using date and 
language criteria. Title review further narrowed literature (reasons: not related to 
depression ^70%, clinical trials of antidepressant medications ^20%, and review/case 
studies ^10%), resulting in 411 unique abstracts for review and forty publications for 
abstraction. Clinical studies were most frequent (n  16) and economic models least 
frequent (n  3); a majority (n  22) reported a U.S. patient population. Thirteen 
publications reported on TRD, thirteen on MDD, and six reported on a “general 
depression” population. Reported deﬁ nitions of TRD varied greatly (one medication
failure (n  2), two medication failures (n  6), HAM-D score (n  3), diagnosis/treat-
ment algorithm (n  1), not deﬁ ned (n  1)). HAM-D (n  12) and MADRS (n  9) 
were the most frequently reported clinical outcomes measures. Cost outcomes were 
discussed in thirteen reports (direct costs (n  11), indirect costs (n  2)). CONCLU-
SIONS: Deﬁ nitions of TRD or CD reported in the literature vary substantially, and 
studies examining productivity of patients were conﬁ ned to generic depression or
MDD populations and would not be directly comparable to a CD or TRD population. 
Additional research is necessary to better deﬁ ne the cost and patient burden of 
TRD.
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OBJECTIVES: To assess the prevalence of insomnia among ﬁ ve large European 
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24,25–34,35–44,45–54,55–64,65–69yrs) strata 
in respective countries, ensured by sampling and intensive panel management. The
survey collected information on select health conditions (incl. insomnia/sleeping-
problems; in the past 12-months), quality of life and health care-utilization. RESULTS:
Total of over 160,000 adult individuals in the European Healthcare Panel com-
pleted survey in the ﬁ ve European nations. Prevalence of Insomnia varied widely
between these 5 nations, as follows (All, Male, Female, % individuals): Netherlands:
13.5%,9.2%,18.0%; Italy: 18.5%,13.3%,23.6%; U.K: 19.3%,14.7%,24.0%;
Germany: 21.6%,16.2%,27.0%; France: 27.6%,19.9%,35.0%. Within each country, 
burden of Insomnia varied by age and gender; distribution among male (18–24,
25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands: 6.4%,8.5%,8.1%,
10.9%,11.0%,8.9%; Italy: 11.1%,8.9%,12.6%,15.7%,16.1%,18.9%; U.K: 9.8%,
10.8%,16.6%,18.1%,17.0%,12.9%; Germany: 12.8%,14.1%,17.1%,19.6%,18.0%,
11.6%; France: 15.9%,17.8%,21.2%,24.0%,19.5%,18.9%; distribution among 
female (18–24,25–34,35–44,45–54,55–64,65 yrs: % pts) was: the Netherlands:
8.5%,12.5%,15.5%,23.7%,23.4%,25.6%; Italy: 16.9%,19.1%,22.4%,28.0%,
27.2%,27.2%; U.K: 17.1%,18.2%,23.0%,30.1%,30.0%,24.8%; Germany: 23.3%,
23.5%,26.5%,32.0%,27.6%,26.2%; France: 28.5%,29.6%,34.2%,39.9%,40.3%,
37.2%. General Practitioners were the primary point of diagnosis and source of treat-
ment, even though this statistic varied between the countries. CONCLUSIONS: Preva-
lence of insomnia appears to be substantial in the studied European nations, with 
France bearing the most burden (one-in-ﬁ ve and one-in-three males and females
respectively in France suffered from this condition). Prevalence peaked among the 
45–64 age-group across the countries. Females had substantially higher disease burden
across the countries, amounting to as much as 1.5 to 2 times more than their male
counterparts in certain age groups.
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OBJECTIVES: The deﬁ nition of chronic migraine (CM), as opposed to episodic 
migraine, has evolved over 20 years of clinical study. This systematic review summa-
rized population-based studies reporting CM prevalence and examined how variations 
in deﬁ nitions affected estimates. METHODS: We conducted a systematic search 
of PubMed, Cochrane, and EMBASE. Search terms included chronic migraine, 
transformed migraine, chronic headache, and prevalence. We included population-
based studies in adults and mixed adults/adolescents that estimated CM prevalence
(or provided information to calculate estimates). We deﬁ ned chronicity as a minimum
headache frequency of 10 per month or reported “daily” headache. Where equivalent, 
we combined diagnostic criteria and deﬁ nitions. Findings were qualitatively summa-
rized. RESULTS: Sixteen publications representing 12 unique studies were identiﬁ ed.
